Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha.
Animals
Blood Proteins
/ metabolism
Chromatography, High Pressure Liquid
/ methods
Cytochrome P-450 Enzyme Inhibitors
/ pharmacology
Cytochrome P-450 Enzyme System
/ metabolism
Humans
Isoenzymes
/ drug effects
Male
Microsomes, Liver
/ metabolism
Neuroprotective Agents
/ isolation & purification
Permeability
/ drug effects
Plant Extracts
/ isolation & purification
Protein Binding
/ drug effects
Rats
Rats, Sprague-Dawley
Withania
/ chemistry
Withanolides
/ isolation & purification
Ashwagandha
CYP inhibition
Cytochrome P450 phenotyping
Plasma protein binding
Withania somnifera
Withanone
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
24 Apr 2021
24 Apr 2021
Historique:
received:
11
07
2019
revised:
01
10
2020
accepted:
11
01
2021
pubmed:
19
1
2021
medline:
3
9
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
Withanone (WN), an active constituent of Withania somnifera commonly called Ashwagandha has remarkable pharmacological responses along with neurological activities. However, for a better understanding of the pharmacokinetic and pharmacodynamic behavior of WN, a comprehensive in-vitro ADME (absorption, distribution, metabolism, and excretion) studies are necessary. A precise, accurate, and sensitive reverse-phase ultra-performance liquid chromatographic method of WN was developed and validated in rat plasma for the first time. The developed method was successfully applied to the in-vitro ADME investigation of WN. The passive permeability of WN was assayed using PAMPA plates and the plasma protein binding (PPB) was performed using the equilibrium dialysis method. Pooled liver microsomes of rat (RLM) and human (HLM) were used for the microsomal stability, CYP phenotyping, and inhibition studies. CYP phenotyping was evaluated using the specific inhibitors. CYP inhibition study was performed using specific probe substrates along with WN or specific inhibitors. WN was found to be stable in the simulated gastric and intestinal environment and has a high passive permeability at pH 4.0 and 7.0 in PAMPA assay. The PPB of WN at 5 and 20 μg/mL concentrations were found to be high i.e. 82.01 ± 1.44 and 88.02 ± 1.15%, respectively. The in vitro half-life of WN in RLM and HLM was found to be 59.63 ± 2.50 and 68.42 ± 2.19 min, respectively. CYP phenotyping results showed that WN was extensively metabolized by CYP 3A4 and1A2 enzymes in RLM and HLM. However, the results of CYP Inhibition studies showed that none of the CYP isoenzymes were potentially inhibited by WN in RLM and HLM. The in vitro results of pH-dependent stability, plasma stability, permeability, PPB, blood partitioning, microsomal stability, CYP phenotyping, and CYP inhibition studies demonstrated that WN could be a better phytochemical for neurological disorders.
Identifiants
pubmed: 33460762
pii: S0378-8741(21)00045-3
doi: 10.1016/j.jep.2021.113819
pii:
doi:
Substances chimiques
Blood Proteins
0
Cytochrome P-450 Enzyme Inhibitors
0
Isoenzymes
0
Neuroprotective Agents
0
Plant Extracts
0
Withanolides
0
Cytochrome P-450 Enzyme System
9035-51-2
withanone
GY036XA633
Ashwagandha
V038D626IF
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
113819Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.